Abstract:Metformin, an ancient drug commonly used for treating type II diabetes, has been associated to anti-cancer capacity in a variety of developing cancers, though the mechanism remains elusive. Here, we aimed to examine the inhibitory effect of metformin in osteosarcoma. Herein, we demonstrated that metformin treatment blocked proliferation progression by causing accumulation of G2/M phase in U2OS and 143B cells. Furthermore, metformin treatment triggered programmed cell death process in osteosarcoma cell lines. Further research indicated the induction of apoptosis and autophagy triggered by metformin could remarkably attenuate after the treatment of ROS scavenger NAC and JNK inhibitor SP600125. Additionally, our results showed that NAC-suppressed JNK/c-Jun signaling pathway could have been activated through metformin treatment. Lastly, metformin could inhibit osteosarcoma growth under safe dose in vivo. Thus, we propose that metformin could induce cell cycle arrest as well as programmed cell death, including apoptosis and autophagy, through ROS-dependent JNK/c-Jun cascade in human osteosarcoma. This metformin-induced pathway provides further insights into its antitumor potential molecular mechanism and illuminates potential cancer targets for osteosarcoma.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the anti - tumor effect of metformin in human osteosarcoma (OS) cells and its mechanism. Specifically, the researchers aimed to verify whether metformin can inhibit the proliferation of osteosarcoma cells by inducing cell - cycle arrest, apoptosis and autophagy, and whether these effects depend on the activation of the ROS/JNK signaling pathway. ### Research Background and Problem Osteosarcoma is the most common malignant bone tumor, which mostly occurs in children, adolescents and young adults. Although progress has been made in chemotherapy combined with surgical treatment, the 5 - year survival rate of patients is still low, especially for patients with metastases. Therefore, it is particularly important to find more effective treatment methods. Metformin, as a commonly used type 2 diabetes drug, has been found to have potential anti - cancer abilities in recent years, especially in melanoma and pancreatic cancer. However, its specific mechanism of action in osteosarcoma is still unclear. ### Main Research Questions 1. **The influence of metformin on the proliferation of osteosarcoma cells**: The researchers first explored whether metformin can inhibit the proliferation of osteosarcoma cells. 2. **The influence of metformin on the cell cycle**: Further analyze whether metformin can cause G2/M - phase arrest in osteosarcoma cells. 3. **The influence of metformin on cell death**: Study whether metformin can induce apoptosis and autophagy in osteosarcoma cells. 4. **The mechanism of action of metformin**: Explore whether metformin exerts the above - mentioned effects through the ROS/JNK signaling pathway. ### Experimental Methods - **Cell viability detection**: Use the CCK - 8 method to detect the survival rate of cells after treatment with different concentrations of metformin. - **Clone formation experiment**: Evaluate the influence of metformin on the cell clone - forming ability. - **Cell - cycle analysis**: Detect the cell - cycle distribution by flow cytometry. - **Apoptosis detection**: Use Hoechst staining and Annexin V/PI double - staining method to detect cell apoptosis. - **Mitochondrial membrane potential detection**: Detect the change of mitochondrial membrane potential by JC - 1 staining. - **Autophagy detection**: Detect the formation of autophagosomes by GFP - LC3 fluorescent dots, and detect the expression of autophagy - related proteins by Western Blot. - **ROS level detection**: Use the DCFH - DA probe to detect the intracellular ROS level. - **Western Blot**: Detect the phosphorylation level of proteins related to the JNK/c - Jun signaling pathway. - **In vivo experiment**: Establish a nude mouse xenograft tumor model to evaluate the anti - tumor effect of metformin in vivo. ### Results Overview - **Metformin inhibits the proliferation of osteosarcoma cells**: CCK - 8 and clone formation experiments show that metformin can significantly inhibit the proliferation of osteosarcoma cells. - **Metformin causes G2/M - phase arrest**: The results of flow cytometry show that cells accumulate in the G2/M phase after metformin treatment. - **Metformin induces cell apoptosis and autophagy**: The results of Hoechst staining, Annexin V/PI double - staining and JC - 1 staining show that metformin can induce cell apoptosis; the results of GFP - LC3 fluorescent dots and Western Blot show that metformin can induce autophagy. - **Metformin exerts its effect through the ROS/JNK signaling pathway**: The detection with DCFH - DA probe shows that the intracellular ROS level increases after metformin treatment; the results of Western Blot show that metformin can activate the JNK/c - Jun signaling pathway. After pretreatment of cells with the ROS scavenger NAC and the JNK inhibitor SP600125, the anti - tumor effect of metformin is significantly weakened. ### Conclusion Metformin can inhibit the proliferation of osteosarcoma cells, induce cell - cycle arrest, apoptosis and autophagy in vitro and in vivo by activating the ROS/JNK signaling pathway. These findings provide a theoretical basis for further exploring the application of metformin in the treatment of osteosarcoma.

Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma

Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells Via Reactive Oxygen Species-Mediated Apoptosis and Autophagy.

Metformin Induces Ferroptosis byInhibiting UFMylation of SLC7A11 in Breast Cancer

Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro

Inhibition of Autophagy Promotes the Anti-Tumor Effect of Metformin in Oral Squamous Cell Carcinoma

In Vitro and in Vivo Anti-Tumor Effect of Metformin As a Novel Therapeutic Agent in Human Oral Squamous Cell Carcinoma.

Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways

Metformin Sensitises Osteosarcoma to Chemotherapy Via the IGF-1R/miR-610/FEN1 Pathway.

Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo

Metformin Suppresses the Esophageal Carcinogenesis in Rats Treated with NMBzA Through Inhibiting AMPK/mTOR Signaling Pathway

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Buformin Suppresses Osteosarcoma Via Targeting AMPK Signaling Pathway

Inhibiting ROS-TFE3-dependent Autophagy Enhances the Therapeutic Response to Metformin in Breast Cancer

Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling

Fibroblasts Rescue Oral Squamous Cancer Cell from Metformin-Induced Apoptosis Via Alleviating Metabolic Disbalance and Inhibiting AMPK Pathway

Celastrol Induces Apoptosis and Autophagy Via the ROS/JNK Signaling Pathway in Human Osteosarcoma Cells: an in Vitro and in Vivo Study

[The Inhibitory Effect of Metformin on Oral Squamous Cell Carcinoma].

Metformin inhibits growth of human non‑small cell lung cancer cells via liver kinase B‑1‑independent activation of adenosine monophosphate‑activated protein kinase

Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling

Metformin sensitized NSCLC cells to Osimertinib via AMPK-dependent autophagy inhibition.

Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma.